Logo image
Se connecter
Durvalumab Induces Sustained Survival Benefit After Concurrent Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
Article de revue   Avec comité de lecture

Durvalumab Induces Sustained Survival Benefit After Concurrent Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

Jean-Louis Pujol
Journal of clinical oncology, Vol.40(12), pp.1271-1274
20/04/2022
PMID: 35239424

Résumé

Life Sciences & Biomedicine Oncology Science & Technology

Indicateurs

1 Consultations de la notice

Détails

Logo image